

BIBLIOGRAPHY

FRIDOLIN SULSER

BIBLIOGRAPHY

1. Gross, F. and Sulser, F.: Verstaerkung und Normalisierung der blutdrucksteigernden Wirkung von Renin an der Ratte. Heiv. Physiol. Acta 12: C75 - C77,1954.
2. Gross, F., Noelpp, B., Sulser, F., Doebelin, R. and Kuendig, R.: Vergleichende Untersuchungen ueber die medi kamentose Beeinflussung verschiedener Formen von experimenteller Hypertension. Kim. Wschr. 33: 372 - 378, 1955.
3. Suiser, F.: Ausloesung und Beeinflussung verschiedener Formen von endocriner Hypertension an der Ratte. inaug. Diss. Birkhaeuser, Basle, 1955.
4. Sulser, F. and Gross, F., Pressorische Substanzen in den Nieren von Ratten mit sogn. "Endocrine Kidney" nach Selje. Heiv. Physiol. Acta 14: C45 - C47,1956.
5. Gross, F. and Sulser, F.: Wirkungsverstaerkung von Renin and Nierenextrakt an der niereniosen Ratte. Arch. Exper. Path. u. Pharmakol. 229: 338 - 347, 1956.
6. Gross, F. and Sulser, F.: Pressorische Substanzen in den Nieren experimenteil hypertonischer Ratten. Arch. Exper. Path. u. Pharmakol. 229: 381 - 388, 1956.
7. Gross, F., Loustalot, P. and Sulser, F.: Die Bedeutung von Kochsalz fuer den Cortexonhochdruck der Ratte urid den Gehalt der Nieren an pressorischen Substanzen. Arch. Exper. Path. u. Pharmakol. 229: 374 - 380, 1956.
8. Gross, F. and Sulser, F.: Der Einfluss der Nebennieren auf die blutdrucksteigernde Wirkung von Renin und auf pressorische Substanzen in den Nieren. Arch. Exper. Path. u. Pharmakol. 230: 274 - 283, 1957.

Fridolin Sulser, M.D.
Curriculum Vitae

9. Sulser, F. and Wilbrandt, W., Die Wirkung von Corticosteroiden und Herzglykosiden auf Jonentransporte am Erythrozyten. *Helv. Physiol. Acta* 16: C37 - C39, 1957.
10. Kunz, H.A. and Sulser, F.: Beziehung Zwischen Nebennieren und aktivem Kationentransport. *Experientia* 13: 365 - 367, 1957.
11. Gantenbein, R., Sulser, F. and Wilbrandt, W.: Antagonistische Wirkung von Herzglykosid und Corticosteroid auf die renale Ausscheidung des Natriums. *Helv. Physiol. Acta* 15: C64 - C66, 1957.
12. Kunz, H.A. and Sulser, F.: Beziehung Zwischen Nebennieren und aktivem Kationentransport. *Experientia* 14: 278 - 279, 1958.
13. Bronstein, J., Sulser, F., Kunz, H.A. and Wilbrandt, W.: Die Wirkung von K-Strophanthosid und Nebennierensteroiden auf den Natriumtransport durch die isolierte Froschhaut. *Helv. Physiol. Acta* 16: C] - C10, 1958.
14. Sulser, F., Gantenbein, R., Kunz, H.A. and Wilbrandt, W.: Zur Frage einer antagonistischen Wirkung zwischen Herzglykosiden und Corticosteroiden auf die Electrolytausscheidung der Niere. *Arch. Exper. Path. u. Pharmacol.* 235: 400 - 411, 1959.
15. Sulser, F.: Die Wirkung von Herzglykosiden und Calcium auf den Kalium Transport im Herzmuskel. *Experientia* 15: 97 - 98, 1959.
16. Sulser, F., Finger, K.F. and Brodie, B.B.: Inhibition of reserpine tranquilizing effects by stress. *Pharmacologist* 1: 74, 1959.
17. Sulser, F. and Brodie, B.B.: Is reserpine tranquilization linked to change in brain serotonin or brain norepinephrine? *Science* 131: 1440 - 1441, 1960.
18. Brodie, B. B., Finger, K. F., Orleans, F. B., Quinn, G. P. and Sulser, F.: Evidence that tranquilizing action of reserpine is associated with changes in brain serotonin and not in brain norepinephrine. *J. Pharmacol. Exp. Ther.* 129: 250 - 256, 1960.
19. Sulser, F. and Watts, J., On the antireserpine actions of imipramine. *Acta Internat. Meeting on the Techniques for the Study of psychotropic Drugs, Bologna, Italy, 1960,, p.* 85 - 87.
20. Orleans, F.B., Sulser, F. and Brodie, B.B.: Depletion of brain norepinephrine by reserpine without producing sedation. *Fed. Proc.* 19: 268, 1960.
21. Sulser, F., Watts, J. and Brodie, B.B., Antagonistic actions of imipramine and reserpine on central nervous system. *Fed. Proc.* 19: 268, 1960.

Fridolin Sulser, M.D.
Curriculum Vitae

22. Bogdanski, D.F., Sulser, F. and Brodie, B.B.: Comparative action of reserpine, tetrabenazine and chlorpromazine on central parasympathetic activity. *J. Pharmacol. Exp. Ther.* 132: 176-182, 1961.
23. Brodie, B.B., Sulser, F. and Costa, E.: Psychotherapeutic drugs. *Ann. Rev. Med.* 12: 349-368, 1961.
24. Brodie, B.B., Sulser, F. and Costa, E.: Theories on mechanism of action on psychotherapeutic drugs. *Symp. Extrapyram. System. Montreal, 1961*, p. 183-189.
25. Sulser, F., Watts, J. and Brodie, B.B.: Blocking of reserpine action by imipramine, a drug devoid of stimulating effects in normal animals. *Fed. Proc.* 20: 321, 1961.
26. Sulser, F. and Brodie, B.B.: On the mechanism of antidepressant action of imipramine. *Biochem. Pharmacol.* 8: 48, 1961.
27. Sulser, F., Watts, J. and Brodie, B.B.: On the mechanism of antidepressant action of imipramine-like drugs. *Ann. N.Y. Acad. Sci.* 96: 270 - 296, 1962.
28. Gillette, J.R., Dingell, J.V., Sulser, F., Kuntzman, R. and Brodie, B.B.: Isolation from rat brain of a metabolic product, desmethylimipramine, that mediates the antidepressant activity of imipramine. *Experientia* 17: 417 - 420, 1961.
29. Brodie, B.B., Bickel, M.H. and Sulser, F.: Desmethylimipramine, a new type of antidepressant drug. *Med. Exp.* 5: 454 - 458, 1961.
30. Sulser, F., Bickel, M.H. and Brodie, B.B.: On the mechanism of antidepressant action of imipramine. *Proc. First Int. Pharmacol. Meeting, Stockholm, 1961*. Pergamon Press, Oxford, 1962, 8: 123- 129, 1962.
31. Sulser, F. and Brodie, B.B.: On the mechanism of action of a new type of antidepressant drug which does not block monoamine oxidase. *Chicago Med.* 65: 9-11, 1962.
32. Dingell, J.V., Sulser, F. and Gillette, J.R.: Metabolism of imipramine in rats and rabbits. *Fed. Proc.* 21: 184a, 1962.
33. Sulser, F. and Bickel, M.H.: On the role of brain catecholamines in the antireserpine action of desmethylimipramine. *Pharmacologist* 4: 178, 1962.
34. Bickel, M.H., Sulser, F. and Brodie, B.B.: Monomethyl analogues of phenothiazines which exert a potent desmethylimipramine-like antidepressant action in rats. *Pharmacologist* 4: 159 - 160, 1962.

Fridolin Sulser, M.D.
Curriculum Vitae

35. Bickel, M.H., Sulser, F. and Brodie, B.B.: Conversion of tranquilizers to antidepressants by removal of one N-methyl group. *Life Sciences* 4: 247 - 253, 1963.
36. Dingell, J.V., Sulser, F. and Gillette, J.R.: Species differences in the metabolism of imipramine and desmethylimipramine. *J. Pharmacol. Exp. Ther.* 143: 14 - 22, 1964.
37. Kunz, H.A., Sulser, F. and Wilbrandt, W.: Ueber die Wirkung von K-Strophanthosid auf die renale Elektrolytausscheidung beider Ratten. *Helv. Physiol. Pharmacol. Acta* 21: 245 - 258, 1964.
38. Sulser, F., Bickel, M.H. and Brodie, B.B.: The action of desmethylimipramine in counteracting sedation and cholinergic effects of reserpine-like drugs. *J. Pharmacol. Exp. Ther.* 144: 321 - 330, 1964.
39. Sulser, F. and Soroko, F.: On the role of rate of brain NE release in the antibenzoquinoline action of desmethylimipramine. *Pharmacologist* 6: 196, 1964.
40. Sulser, F. and Soroko, F.: On the role of rate of brain norepinephrine release in the antibenzoquinoline action of desipramine. *Psychopharmacologia* 8: 191 - 200, 1965.
41. Sulser, F. and Dingell, J.V.: The role of adrenergic mechanisms in the mode of action of tricyclic antidepressants (biochemical and metabolic considerations), In: *Antidepressant Drugs of Non-MAO Inhibitor Type*, Proc. of a Workshop, Washington, DC, ed. D.H. Efron and S.S. Kety, Pharmacology Unit, NIMH, NIH, pp.1 - 19, 1966.
42. Sulser, F., Owens, M.L. and Dingell, J.: On the mechanism of amphetamine potentiation by desipramine (DM1). *Life Sciences* 5: 2005 - 2010, 1966.
43. Sulser, F., DeEncarnacao, P., Owens, M.L. and Dingell, J.V.: The role of storage and synthesis of brain norepinephrine in the central action of desipramine and d-amphetamine. *Pharmacologist* 8: 214, 1966.
44. Dingell, J.V., Owens, M.L., Norvich, M.R. and Sulser, F.: On the role of norepinephrine biosynthesis in the central action of amphetamine. *Life Sci.* 6:1155 - 1162, 1967.
45. Sulser, F., Owens, M.L. and Dingell, J.V.: In vivo modification of biochemical effects of reserpine by desipramine in the hypothalamus of the rat. *Pharmacologist* 9: 312, 1967.
46. Sulser, F.: Mode of action of tricyclic antidepressants and substituted phenothiazines on central adrenergic mechanisms. *Internat. Symp. on Mechanism*

Fridolin Sulser, M.D.
Curriculum Vitae

- of action and Metabolism of Phenothiazines and Related Compounds. Paris, France, 1967, pp. 17 - 20.
47. Sulser, F. and Dingell, J.V.: Potentiation and blockade of the central action of amphetamine by chlorpromazine. *Biochem. Pharmacol.* 17: 634 - 634, 1968.
 48. Sulser, F.: Discussion of the effects of benzoquinolizines and ring-substituted aralkylamines on serotonin metabolism. *Adv. Pharmacol.* 6: 170- 171, 1968.
 49. Sulser, F., Owens, M.L., Norvich, M.R. and Dingell, J.V.: The relative role of storage and synthesis of brain norepinephrine in the psychomotor stimulation evoked by amphetamine or by desipramine and tetrabenazine. *Psychopharmacologia* 12: 322- 332, 1958.
 50. Sulser, F. and Dingell, J.V.: Adrenergic mechanisms in the central action of tricyclic antidepressants and substituted phenothiazines. *Agressologie* 9: 281 - 288, 1968.
 51. Sulser, F. and Bass, A.D.: Pharmacodynamic and biochemical considerations on the mode of action of reserpine-like drugs. In: *Psychopharmacology - A Review of Progress*, U.S. Dept. of Health, Education and Welfare, Washington, D.C., pp. 1065 - 1075, 1968.
 52. Sulser, F., Owens, M.L., Strada, S.J. and Dingell, J.V.: Modification by desipramine of the availability of norepinephrine released by reserpine in the hypothalamus of the rat. *J. Pharmacol. Exp. Ther.* 168: 272 - 282, 1969.
 53. Sanders-Bush, E. and Sulser, F.: Selective effects of drugs on brain serotonin at different functional sites. *Pharmacologist* 10: 210, 1968.
 54. Strada, S.J. and Sulser, F.: Modification of the availability of norepinephrine (NE) in the hypothalamus of the unanesthetized rat. *Fed. Proc.* 28: 28: 795, 1969.
 55. Sanders-Bush, E. and Sulser, F.: Biochemical and metabolic considerations in the mode of action of p-chloroamphetamine. In: *International Symposium on Amphetamines and Related Compounds*, eds., E. Costa and S. Garattini, Raven Press, 1970, pp. 349 - 355.
 56. Sanders-Bush, E. and Sulser, F.: Differential effects of psychotropic drugs on release and metabolism of endogenous 5-hydroxy-tryptamine and 5-hydroxytryptamine-C¹⁴ in brain. *Biochem. Pharmacol.*
 57. Sulser, F. and Sanders-Bush, E.: Biochemical and metabolic considerations concerning the mechanism of action of amphetamine and related compounds. In: *Psychotomimetic Drugs*, ed., D.H. Efron, Raven Press, New York, pp. 83 - 103, 1970.

Fridolin Sulser, M.D.
Curriculum Vitae

58. Sulser, F. and Sanders-Bush, E.: Biochemical and pharmacological considerations on the mode of action of p-chlorinated amphetamine derivatives. Fourth International Congress on Pharmacology, Basle, 1969.
59. Palmer, E., Sulser, F. and Robison, G.A.: The effect of neurohumoral agents on the level of cyclic AMP in different brain areas in vitro. *Pharmacologist* II: 258, 1969.
60. Sanders-Bush, E. and Sulser, F.: On the mechanism of action of p-chloroamphetamine. *Pharmacologist* 11: 258, 1969.
61. Strada, S., Sanders-Bush, E. and Sulser, F.: Comparative studies on the mode of action of amphetamine and p-chloroamphetamine. *Pharmacologist* 11: 258, 1969.
62. Sanders-Bush, E. and Sulser, F.: p-Chloroamphetamine: In vivo investigations on the mechanism of action of the selective depletion of cerebral serotonin. *J.Pharmacol. Exp. Ther.* 175: 419 -426, 1970.
63. Strada, S.J., Sanders-Bush, E. and Sulser, F.: p-chloroamphetamine: Temporal relationship between psychomotor stimulation and metabolism of brain norepinephrine. *Biochem. Pharmacol.* 19: 2621 - 2629, 1970.
64. Strada, S.J. and Sulser, F.: In vivo release of norepinephrine in the hypothalamus: Modification by p-chloroamphetamine and amphetamine. *Fed. Proc.* 29: 963, 1970.
65. Palmer, G.C., Dobbs, J.W., Sulser, F. and Robison, G.A.: Effect of drugs on cyclic AMP formation in rat hypothalamus in vitro. First Neurochemical Society Meeting, Albuquerque, New Mexico, 1970.
66. Miller, K.W., Freeman, J.J., Dingell, J.V. and Sulser, F.: On the mechanism of amphetamine potentiation by iprindole. *Experientia* 26: 863 - 864, 1970.
67. Palmer, G.C., Robison, G.A. and Sulser, F.: Modification by psychotropic drugs of the cyclic AMP response to norepinephrine in rat brain. *Biochem. Pharmacol.* 20: 236-239, 1971.
68. Palmer, G.C., Robison, G.A., Manian, A.A. and Sulser, F.: Modification by psychotropic drugs on the cyclic AMP response to norepinephrine (NE) in rat brain. *Pharmacologist* 12: 256, 1970.
69. Freeman, J., Miller, K.W. and Sulser, F.: On the mechanism of amphetamine potentiation by iprindole. *Pharmacologist* 12: 226, 1970.

Fridolin Sulser, M.D.
Curriculum Vitae

70. Strada, S.J. and Sulser, F.: Comparative effects of p-chloroamphetamine and amphetamine on metabolism and in vivo release of ³H-norepinephrine in the hypothalamus. *Europ. J. Pharmacol.* 15: 45-51,1971.
71. Sulser, F. and Sanders-Bush, E.: Effect of drugs on amines in the CNS. *Ann. Rev. Pharmacol.* 11: 209 - 230, 1971.
72. Strada, S.J. and Sulser, F.: Effect of monoamine oxidase inhibitors on metabolism and in vivo release of ³H-norepinephrine from the hypothalamus. *Europ. J. Pharmacol.* 18, 303 - 308, 1972.
73. Taylor, W.A., Freeman, J.J. and Sulser, F.: On the mechanism of norepinephrine depletion by amphetamine in rat brain. *Fed. Proc.* 30: 677, 1971.
74. Sanders-Bush, E. and Sulser, F.: Some metabolic and neurochemical aspects of the pharmacology of amphetamine and p-chloroamphetamine. In: *Current Concepts on Amphetamine Abuse, Proceedings of a Workshop, Duke University, Washington, D.C., Government Printing Office, pp. 69-76, 1972.*
75. Palmer, G.C., Robison, G.A., Manian, A.A. and Sulser, F.: Modification by psychotropic drugs of the cyclic AMP response to norepinephrine in the rat brain in vitro. *Psychopharmacologia* 23: 201-211,1972.
76. Palmer, G.C., Sulser, F. and Robison, G.A.: The effect of neurohumoral and adrenergic agents on cyclic AMP levels in various areas of the rat brain in vitro. *Neuropharmacology* 12: 327-338,1973.
77. Strada, S.J. and Sulser, F.: Effect of monoamine oxidase inhibitors on metabolism and in vivo release of ³H-norepinephrine from the hypothalamus. *Europ. J. Pharmacol.* 18: 303-308, 1972.
78. Schmidt, J.M., Schmidt, D.E., Sulser, F. and Robison, G.A.: Estimation of cyclic AMP in discrete brain regions through the use of microwave irradiation. In: *Physiology and Pharmacology of Cyclic AMP, an International Conference, Milan, 1972.*
79. Gallager, D.W., Sanders-Bush, E. and Sulser, F.: Dissociation between behavioral effects and changes in metabolism of cerebral serotonin (5HT) following delta ⁹-tetrahydrocannabinol (THC). *Pharmacologist* 13: 2296, 1971.
80. Freeman, J.J., Sanders-Bush, E. and Sulser, F.: Further studies on the mechanism of amphetamine potentiation by iprindole. *Pharmacologist* 13: 255, 1971.
81. Taylor, W.A. and Sulser, F.: Effect of intraventricularly administered amphetamine and its hydroxylated metabolites on the metabolism of ³H norepinephrine in brain. *Pharmacologist* 13: 230, 1971.

Fridolin Sulser, M.D.
Curriculum Vitae

82. Sanders-Bush, E., Bushing, J. and Sulser, F.: p-Chloroamphetamine: Inhibition of cerebral tryptophan hydroxylase. *Biochem. Pharmacol.* 21: 1501-1510,1972.
83. Gallager, D.W., Sanders-Bush, E. and Sulser, F.: Dissociation between behavioral effects and changes in metabolism of cerebral serotonin following delta ⁹ tetrahydrocannabinol. *Psychopharmacologia* 26: 337-345, 1972.
84. Freeman, J.J. and Sulser, F.: Iprindole-amphetamine interactions: The role of aromatic hydroxylation of amphetamine in its mode of action. *J. Pharmacol. Exp. Ther.* 183: 307-315, 1972.
85. Taylor, W.A. and Sulser, F.: Effects of amphetamine and its hydroxylated metabolites on cerebral noradrenergic mechanisms. *J. Pharmacol. Exp. Ther.* 185: 620-632,1973.
86. Sanders-Bush, E., Bushing, J.A. and Sulser, F.: Long-term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain. *European J. Pharmacol.* 20: 385-388,1972.
87. Sanders-Bush, E., Blumberg, J.B. and Sulser, F.: Biochemical effects of chlorinated amphetamine derivatives. *Proc. Collegium Internationale Neuropsychopharmacologicum*, Copenhagen, Denmark, 1972, In: *Psychopharmacologia* 26 (Suppl.): 34, 1972.
88. Taylor, W.A. and Sulser, F.: Effects of intraventricularly administered l-d- and dl-p-hydroxyamphetamine (POH) on behavior and cerebral catecholamine. *Fifth Internat. Congress on Pharmacology*, p. 230, 1972.
89. Freeman, J.J. and Sulser, F.: On the peripheral mode of action of amphetamine and desipramine. *Fifth Internat. Congress on Pharmacology*, p. 72,1972.
90. Sanders-Bush, F. and Sulser, F.: p-Chloroamphetamine: Studies on the biochemical mechanism of its action on cerebral serotonin. **In:** *Psychopharmacology, Sexual Disorders and Drug Abuse*, North Holland Publishing Co., Amsterdam and Avicenum Press, Praha, pp. 607-613,1973.
91. Sulser, F. and Sanders-Bush, E.: Recent advances in the biochemical pharmacology of amphetamine and its chlorinated derivatives. *Soc. for Neuroscience, Second Ann. Meeting, Houston, Texas*, p. 175, 1972.
92. Blumberg, J.B., Taylor, R.E. and Sulser, F.: Modification by antipsychotic drugs of the cyclic 3',5-AMP (cAMP) response to d-lsd in rat brain following microwave irradiation. *Fed. Proc.* 32: 496, 1973.

Fridolin Sulser, M.D.
Curriculum Vitae

93. Sulser, F. and Sanders-Bush, E.: Halogen substitution of amphetamine-like drugs: Biochemical and pharmacological consequences. In: *Frontiers in Catecholamine Research*, Pergamon Press, pp. 995-1001, 1973.
94. Sulser, F.: On the mode of action of antidepressants. In: *Psychopharmacologic Treatment in Psychiatry*, Marcel Dekker, New York, H.C.B. Denber, ed. 97-120, 1975.
95. Sanders-Bush, E. and Sulser, F.: On the mechanism of brain 5-hydroxytryptamine depletion by p-chloroamphetamine and related drugs and the specificity of their action. *Advances Biochem. Psychopharmacol.* 10: 185-194, 1974.
96. Freeman, J.J. and Sulser, F.: Formation of p-hydroxynorephedrine in brain following intraventricular administration of p-hydroxyamphetamine. *Neuropharmacology* 13: 1187-1190, 1974.
97. Smith, H.E., Burrows, E.P., Miano, J.D., Mount, C.D., Sanders-Bush, E. and Sulser, F.: The action of (S)- and (R)-para-substituted amphetamine hydrochlorides and alpha (S)- and alpha (R)-p-chloronorephedrine and alpha (S)- and alpha (R)-p-chloro-norpseudoephedrine hydrochlorides on the level of 5-hydroxytryptamine and the activity of tryptophan hydroxylase in rat brain. *J. Med. Chem.* 17: 416-421, 1974.
98. Sulser, F. and Sanders-Bush, E.: Halogen substitution of amphetamine like drugs: Biochemical and pharmacological consequences. *Life Sciences* 13: No. 8, clvii, 1973.
99. Stawarz, R.F., Robinson, S., Sulser, F. and Dingell, V.J.: On the significance of the increase of homovanillic acid (HVA) caused by antipsychotics in corpus striatum and limbic forebrain. *Fed. Proc.* 33: 244, 1974.
100. Blumberg, J.B. and Sulser, F.: The effect of antipsychotic drugs on the cyclic 3',5'-adenosine monophosphate (cAMP) system in rat limbic forebrain. *Fed. Proc.* 33: 446, 1974.
101. Freeman, J.J. and Sulser, F.: The role of para-hydroxylation of amphetamine in its peripheral mode of action. *J. Pharmacol. Pharmacol.* 27: 38-42, 1975.
102. Sulser, F., Stawarz, R.J. and Blumberg, J.B.: The limbic forebrain: The role of catecholamines and cyclic AMP in the action of antipsychotics. *J. Pharmacol. (Paris)* 5 (I): 115-116, 1974.
103. Vetulani, J., Dingell, J.V. and Sulser, F.: Effect of chronic treatment with desipramine (DM1) and iprindole (IP) on the norepinephrine (NE) sensitive

Fridolin Sulser, M.D.
Curriculum Vitae

- adenylate cyclase system in slices of the rat limbic forebrain. *Pharmacologist* 16: 546, 1974.
104. Blumberg, J.B., Taylor, R.E. and Sulser, F.: Blockade by pimozide of a norepinephrine-sensitive adenylylase in the limbic forebrain: Possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics. *J. Pharmacol. Pharmacol.* 27:125-128, 1975.
 105. Sulser, F., Stawarz, R.J. and Blumberg, J.B.: The limbic forebrain: The role of catecholamines and cyclic AMP in the mode of action of antipsychotics. In: *Neuropsychopharmacology, Excerpta Medica International Congress Series*, pp. 873-881, 1975.
 106. Gallager, D.W., Sanders-Bush, E., Aghajanian, G.K. and Sulser, F.: An evaluation of the use of intraventricularly administered 5-hydroxytryptamine as a marker for endogenous 5-hydroxytryptamine. *Brain Res.* 93, 111-122, 1975.
 107. Sanders-Bush, E., Bushing, J.A. and Sulser, F.: Long-term effects of p-chloramphetamine and related drugs on central serotonergic mechanisms. *J. Pharmacol. Exp. Ther.* 192: 33-41, 1975.
 108. Vetulani, J., Stawarz, R.J., Blumberg, J.B. and Sulser, F.: Adaptive mechanisms in the norepinephrine-sensitive cyclic AMP generating system in slices of the rat limbic forebrain. *Fed. Proc.* 34: 269, 1975.
 109. Stawarz, R.J., Hill, H., Robinson, S., Setler, P., Dingell, J.V. and Sulser, F.: On the significance of the increase in homovanillic acid (HVA) caused by antipsychotics in corpus striatum and limbic forebrain. *Psychopharmacologia* 43, 125-130, 1975.
 110. Sulser, F. and Vetulani, J.: Molecular pharmacology of psychotropic drugs: The role of striatal and limbic catecholaminergic mechanisms and cyclic AMP in the mode of action of antipsychotics and other psychotropic drugs. *Max-Planck Symposium*, Gottingen, 1975.
 111. Blumberg, J.B., Vetulani, J., Stawarz, R.J. and Sulser, F.: The noradrenergic cyclic AMP generating system in the limbic forebrain: Pharmacological characterization and possible role in the mode of action of antipsychotics. *Europ. J. Pharmacol.* 37: 357-366, 1976.
 112. Vetulani, J. and Sulser, F.: Action of various antidepressant treatment reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. *Nature* 257: 495, 1975.
 113. Vetulani, J., Stawarz, R.J., Dingell, J.V. and Sulser, F.: A possible common mechanism of action of antidepressant treatments: Reduction in the sensitivity

Fridolin Sulser, M.D.

Curriculum Vitae

- of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 293: 109-114, 1976.
114. Vetulani, J., Stawarz, R.J. and Sulser, F.: Adaptive mechanisms of the noradrenergic cyclic AMP generating system of the limbic forebrain of the rat: Adaptation to persistent changes in the availability of norepinephrine. *J. Neurochem.* 27: 661-666, 1976.
 115. Robinson, S.E. and Sulser, F.: Effect of metoclopramide on limbic noradrenergic and striatal and limbic dopaminergic mechanisms. *Pharmacologist* 17,448, 1975.
 116. Vetulani, J., Leith, N.J., Stawarz, R.J. and Sulser, F.: Effect of clonidine on the norepinephrine (NE)-sensitive cyclic AMP generating system in slices of rat spinal cord, brain stem and limbic forebrain and on medial forebrain bundle stimulation. *Pharmacologist* 17: 116,1975.
 117. Smith, H.E., Burrows, E.P., Sanders-Bush, E. and Sulser, F.: Stereochemistry and neurochemical effects of the enantiomers of 0-m- and p-chloroamphetamine. *Med.Chemistry Meeting, Mexico City, (abstract), 1975.*
 118. Sulser, F.: Reporter's comments on "Cyclic nucleotides and regulation of catécholamine turnover", In: "Chemical tools in catecholamine research", Vol. II,p. 301-304, Elsevier, Excerpta Medica, North Holland, Amsterdam, 1975.
 119. Sulser, F.: Tricyclic Antidepressants: Animal Pharmacology (Biochemical and Metabolic Aspects), In: "Handbook of Psychopharmacology". S. Snyder, L. L. Iversen and S. Iversen, eds., Volume 14, pp. 157-197, Plenum Press, New York, N.Y., 1978.
 120. Sulser, F. and Vetulani, J.: Psychotropic drugs and cyclic AMP in the central nervous system (with particular reference to striatal and mesolimbic structures, In: "Cyclic Nucleotides: Mechanism of action", Wiley and Sons, Ltd., London, H. Cramer and J. Schultz, eds., pp. 337-365, 1977.
 121. Robinson, S.E. and Sulser, F.: The noradrenergic cyclic AMP generating system in the rat limbic forebrain and its stereospecificity for (+) butaclamol. *J. Pharm. Pharmacol.* 28: 645-646, 1976.
 122. Sulser, F.: Pre-clinical psychopharmacology and therapeutics: A two way street training model, Abstracts, 10th Congress of the C.I.N.P.,p. 107, Quebec, Canada, 1976.
 123. Robinson, S.E., Mobley, P.L. and Sulser, F.: The noradrenergic cyclic AMP generating system in the rat limbic forebrain: Stereo-specificity of agonists and antagonists. *Pharmacologist* 18: 220, 1976.

Fridolin Sulser, M.D.
Curriculum Vitae

124. Boissier, J.R. and Sulser, F. (eds): Indoleamines and precursors in depressive states. In: Proc. X Congress of the C.I.N.P., Pergamon Press, Oxford and New York, 1977.
125. Sulser, F.: Preclinical psychopharmacology and therapeutics: A pharmacologists point of view. In: Proc. X Congress of the C.I.N.P. Pergamon Press, Oxford and New York, 165-169, 1977.
126. Sulser, F. and Vetulani, J.: **The noradrenergic cyclic AMP generating system in the limbic forebrain: A functional post-synaptic norepinephrine receptor system and its modification by drugs which either precipitate or alleviate depression.** Anna Monica Foundation - paper, 1977.
127. Vetulani, J., Leith, N.J., Stawarz, R.J. and Sulser, F.: Effect of clonidine on the noradrenergic cyclic AMP generating system in the limbic forebrain and on medial forebrain self-stimulation behavior. *Experientia* 33: 1490-1492, 1977.
128. Smith, H.E., Burrows, E.P., Mobley, P.L., Robinson, S.F. and Sulser, F.: Agonist effect of beta-phenethylamines on the noradrenergic cyclic AMP generating system in rat limbic forebrain. Stereo isomers of p-hydroxynorephedrine. *J. Med. Chem.* 20: 978-981, 1977.
129. Mobley, P.L., Smith, H.E. and Sulser, F.: Modification of the noradrenergic cyclic AMP generating system in the rat limbic forebrain by amphetamine and its hydroxylated metabolites. *Fed. Proc.* 36: 319, 1977.
130. Robinson, S.E., Lotti, V.J. and Sulser, F.: Cyanocyproheptadine: Role of anticholinergic properties in modulating neuroleptic induced elevation of striatal homovanillic acid (HVA). *J. Pharm. Pharmacol.* 29: 564-566, 1977.
131. Sulser, F. and Vetulani, J.: The noradrenergic cyclic AMP generating system in the limbic forebrain: A functional post-synaptic norepinephrine receptor system and its modification by drugs which either alleviate or precipitate depression. In: "Models in Psychiatry and Neurology" Pergamon Press, New York, (I. Hanin & E. Usdin, Eds.) pp.189-199, 1977.
132. Sulser, F., Vetulani, J. and Mobley, P.L.: On the mode of action of antidepressant drugs - Commentary. *Biochem. Pharmacol.* 27: 257-261, 1978.
133. Sulser, F. and Robinson, S.E.: Clinical implications of pharmacological differences among antipsychotics. In: *Psychopharmacology: A generation of progress.* (K. Killam, A. DiMascio and M. Lipton, eds.), Raven Press, N.Y., 943-954, 1978.
134. Sulser, F.: Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which

Fridolin Sulser, M.D.
Curriculum Vitae

- precipitate or alleviate depression: Molecular approaches to an understanding of affective disorders. *Pharmakopsychiat.* 11: 43-52, 1978.
135. Manier, D.H., Gillespie, D.D. and Sulser, F.: Effect of (5)- amphetamine on limbic cyclic AMP responses to (R)-norepinephrine following inhibition of aromatic hydroxylation by iprindole. *Fed. Proc.* 37, 699, 1978.
 136. Sulser, F. and Mobley, P.L.: Biochemical effects of antidepressant drugs in animals. In: "Handbook of Experimental Pharmacology ", Springer Verlag, Berlin, Vol. 5511, pp. 47 1-490, 1980.
 137. Robinson, S.E., Mobley, P.L., Smith, H. E. and Sulser, F.: Structural and steric requirements of beta-phenethylamines as agonists of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 303: 175-180, 1978.
 138. Mobley, P.L., Sanders-Bush, E., Smith, H.E. and Sulser, F.: Modification of the noradrenergic cyclic AMP generating system in the rat limbic forebrain by amphetamine: Role of its hydroxylated metabolites. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 306: 267-273, 1979.
 139. Robinson, S.E., Berney, S.A., Mishra, R. and Sulser, F.: The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: Metoclopramide, thiethylperazine and molindone as pharmacological tools. *Psychopharmacol.* 64: 141-147, 1979.
 140. Mobley, P.L., Mishra, R. and Sulser, F.: Characterization, adaptation and regulatory changes of the norepinephrine receptor coupled adenylate cyclase system in limbic forebrain structures. In: *Catecholamines: Basic and Clinical Frontiers*, E. Usdin, I.J. Kopin and J. Barchas, eds., Pergamon Press, New York, 523-525, 1979.
 141. Sulser, F., Mishra, R. and Mobley, P. L.: Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the central nervous system. In: *Biological Psychiatry Today*, Elsevier/North Holland Biomedical Press, J. Obiols, C. Ballus, E. Gonzalez Moncius, Eds.): p. 100-105, Amsterdam, 1979.
 142. Mishra, R. and Sulser, F.: Role of serotonin reuptake inhibition in the development of subsensitivity of the norepinephrine (NE) receptor coupled adenylate cyclase system. *Comm. Psychopharmacol.* 2: 365-370, 1978.
 143. Mishra, R., Leith, N.J. and Sulser, F.: Desensitization of the norepinephrine receptor coupled adenylate cyclase system following antidepressants which inhibit serotonin (5HT) reuptake. *Pharmacologist* 20: 429, 1978.
 144. Gillespie, D.D., Manier, D.H. and Sulser, F.: Normalization by

Fridolin Sulser, M.D.
Curriculum Vitae

- amphetamine of the reserpine induced hypersensitivity of the noradrenergic cyclic AMP generating system in brain. *Pharmacologist* 20: 430, 1978.
145. Sulser, F.: New cellular mechanisms of antidepressant drugs. In: "New Frontiers of psychotropic drug research", Futura Publishing Co., Mount Kisco, New York, S. Fielding and H. Lai, eds., 1979, pp. 29-50.
146. Gillespie, D.D., Manier, D.H. and Sulser, F.: Electroconvulsive treatment: Rapid subsensitivity of the norepinephrine receptor coupled adenylate cyclase system in brain linked to down regulation of beta adrenergic receptors. *Comm.Psychopharmacol.* 3: 91-195, 1979.
- 147, Mobley, P.L. and Sulser, F.: Norepinephrine stimulated cyclic AMP accumulation in rat limbic forebrain slices: partial mediation by a subpopulation of receptors with neither alpha nor beta characteristics. *European J. Pharmacol* 60: 221-227, 1979.
148. Gillespie, D. D., Manier, D. H. and Sulser, F.: Electroconvulsive treatment (ECT): Rapid development of subsensitivity of the NE receptor coupled adenylate cyclase system. *Fed. Proc.* 38: 1944, 1979.
149. Sulser, F. and Mobley, P. L.: Characteristics and regulation of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain. *Psychopharmacol. Bull.* 16: 33-35, 1980.
150. Sanders-Bush, E.: Meltzer, H.Y. and Sulser, F.: Drugs for the therapy of affective disorders. In: *Pharmacology in Medicine: Principles and Practice* (N.S. Pradhan, R. P. Maickel, S.N. Dutta, Eds.) S.P. Press International, Inc., Bethesda, MD, pp. 338-348, 1986.
151. Janowsky, A., Mishra, R. and Sulser, F.: Effect of nisoxetine on the sensitivity of the norepinephrine receptor coupled adenylate cyclase system in rat brain cortex. *Pharmacologist* 21: 5481, 1979.
152. Mobley, P.L. and Sulser, F.: Altered sensitivity of the norepinephrine receptor coupled adenylate cyclase system in brain tissue after bilateral adrenalectomy. *Pharmacologist* 21: 5471, 1979.
153. Manier, D.H., Gillespie, D.D. and Sulser, F.: Regional recovery from subsensitivity of the norepinephrine receptor coupled adenylatecyclase system in brain. *Pharmacologist* 21: 5491, 1979.
154. Mobley, P.L. and Sulser, F.: Adrenal corticoids regulate sensitivity of noradrenaline receptor coupled adenylate cyclase in brain. *Nature* 286: 608-609, 1980.

Fridolin Sulser, M.D.

Curriculum Vitae

155. Mishra, R., Janowsky, A. and Sulser, F.: Subsensitivity of the NE receptor coupled adenylate cyclase system in brain: Effects of nisoxetine vs.fluoxetine. *Europ. J. Pharmacol.* 60: 379-382, 1979.
156. Sulser, F.: New perspectives on the mode of action of antidepressant drugs. *Trends in Pharmacological Sciences* 1: 92-94, 1979.
157. Sulser, F. and Mobley, P. L.: Down-regulation of noradrenergic receptor function by antidepressant drugs: Functional significance and distinction from antipsychotic drugs. E. Usdin, H. Eckert and I.S.Forrest, eds., Elsevier North Holland, New York, 1980.
158. Gillespie, D.D., Manier, D.H. and Sulser, F.: Amphetamine normalizes reserpine induced supersensitivity of the noradrenaline receptor coupled adenylate cyclase system in brain. *J. Pharm. Pharmacol.*32: 503-504, 1980.
159. Mishra, R., Janowsky, A., and Sulser, F.: Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: Subsensitivity without reduction in beta-adrenergic receptor binding. *Neuropharmacol.* 19: 983-987, 1980.
160. Sulser, F. and Mobley, P.L.: Regulation of central noradrenergic receptor function: New vistas on the mode of action of antidepressant treatments. In: *Neuroreceptors - Basic and Clinical Aspects*, E. Usdin, W.E. Bunney and J.M. Davis, Eds., John Wiley and Sons, Ltd; London, p.p. 55-83, 1981.
161. Sulser, F.: Antidepressant drugs and plasticity of norepinephrine receptor systems in brain. *Am. Soc. Neurochem. Eleventh Ann. Meeting; Houston, TX* 282, 1980 (abstract).
162. Manier, D.H., Gillespie, D.D. and Sulser, F.: Development of and recovery from subsensitivity of the noradrenergic cyclic AMP generating system in brain: Effect of amphetamine following inhibition of its aromatic hydroxylation by iprindole. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 313: 113-118, 1980.
163. Mobley, P.L. and F. Sulser: Adrenal steroids modify the sensitivity of the norepinephrine receptor coupled adenylate cyclase system in brain. *Prog. Neuropsychopharmacol. Supplement* 943, 1980 (abstract).
164. Sulser, F. and Mobley, P.L.: Neurobiological significance of down-regulation of central adrenergic receptor function by antidepressant treatments. *Prog. Neuropsychopharmacol. Supplement* 649, 1980, (Abstract).
165. Mishra, R., Leith, N.J., Steranka, L. and Sulser, F.: The noradrenaline receptor coupled adenylate cyclase system in brain: Lack of modification by changes in the availability of serotonin. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 316: 218-224, 1981.

Fridolin Sulser, M.D.
Curriculum Vitae

166. Sulser, F.: Pharmacology: Current Antidepressants. *Psychiatric Annals* 10: 381-387,1980.
167. Mobley, P.L. and Sulser, F.: Adrenal steroids affect the norepinephrine sensitive adenylate cyclase system in rat limbic forebrain. *European J. Pharmacol.* 65: 321-323,1980.
168. Mishra, R., Janowsky, A. and Sulser, F.: Subsensitivity of the noradrenergic cyclic AMP generating system without reduction in beta adrenergic receptor binding. *Pharmacologist* 22: 116, 1980.
169. Mobley, P.L. and Sulser, F.: Down-regulation of the central noradrenergic receptor system by antidepressant therapies: Biochemical and clinical aspects. In: "Antidepressants: Neurochemical, Behavioral and clinical perspectives, S.J. Enna, T.B. Malick and E. Richelson, eds., Raven Press, New York, 1981, pp. 31-51.
170. Sulser, F.: New Perspectives on the action of antidepressant drugs: Regulation of central adrenergic receptor function. In: *Advances Biol. Psychiat.* 7, 90-99, 1981.
171. Petrie, W.M. and Sulser, F.: Amine hypotheses of depression - a review. In: *Depression and Antidepressants*, E. Friedman, J. Mann and S. Gershon, eds., Plenum Press, New York, 1983.
172. dePaulis, T., Smith, H.E., Betts, C.R., Mobley, P.L., Manier, D.H. and Sulser, F.: Novel synthesis of clozapine analogs and their interaction with clozapine and spiroperidol binding sites. *J. Med. Chem.* 24: 1021-1026, 1981.
173. Mobley, P.L., Manier, D.H., de Paulis, T., Smith, H.E. and Sulser, F.: Structural alterations of the clozapine molecule: Effect on affinity for ³H-spiroperidol and ³H-clozapine binding sites in rat brain. *Fed. Proc.* 40: 4, 1981.
174. Smith, H.E., Betts, C.R., dePaulis, T., Mobley, P.L., Manier, D.H. and Sulser, F.: Synthesis of clozapine analogs and their affinity for clozapine and spiroperidol binding sites in rat brain. 181st Natl. Meeting Am. Chem. Soc. 1981.
175. Mishra, R. and Sulser, F.: The cyclic AMP response to norepinephrine in the limbic forebrain of male and female rats: Effect of desipramine. *Biochem. Pharmacol.* 30: 3126-3128, 1981.
176. Mishra, R., Gillespie, D.D. and Sulser, F.: Down-regulation of the norepinephrine (NE) receptor coupled adenylate cyclase system in brain by oxaprotaline. Abstract, 8th Internatl. Congress of Pharmacology, Tokyo, Japan, 1981.

Fridolin Sulser, M.D.
Curriculum Vitae

177. Sulser, F.: Up- and Down-regulation of noradrenergic receptor systems in brain: Molecular mechanisms and physiological significance. 8th International Congress of Pharmacology, Tokyo, Japan, 1981.
178. Sulser, F.: Antidepressant drug research: Its impact on neurobiology and psychobiology, Giovanni Lorerizini Foundation Lecture, In: Advances Biochem. Psychopharmacol. 31: 1-20, 1982.
179. Janowsky, A., Steranka, L.R., Gillespie, D.D. and Sulser, F.: Role of neuronal signal input in the down-regulation of central noradrenergic receptor function by antidepressant drugs. Soc. Neurosci. 1981 (Abstract).
180. Sulser, F., Janowsky, A. and Mishra, R.: Up- and down-regulation of noradrenergic receptor systems in brain: Molecular mechanisms and physiological significance. In: Advances in Pharmacology and Therapeutics II, Volume 2, Neurotransmitter receptors, H. Yoshida, Y. Hagighana and S. Ebashi, eds. pp. 29-40, Pergamon Press, New York, NY, 1982.
181. Sulser, F. and Mishra, R.: Regulation of central noradrenergic receptor function and its relevance to the therapy of depression. Adv. Biosci. 40: 37-47, 1982.
182. Sulser, F. and Mishra, R.: The discovery of tricyclic antidepressants and their mode of action, In: Discoveries in Pharmacology, M.J. Parnhan and J. Boninvels, eds., Elsevier, North Holland, Vol. I, pp. 233-247, 1983.
183. Mishra, R., Gillespie, D.D., Lovell, R., Robson, R.D. and Sulser, F.: Oxaprotiline: Induction of central noradrenergic subsensitivity by its (+)-enantiomer. Life Sci. 30: 1747-1755, 1982.
184. Harris, T.S., Smith, H.E., Mobley, P.L., Manier, D.H. and Sulser, F.: Affinity of 10-(4-methylpiperazine) dibenz [b] oxazepine for clozapine and spiroperidol binding sites in rat brain. J. Med. Chem. 25: 855-859, 1982.
185. Janowsky, A.J., Steranka, L.R., Gillespie, D.D. and Sulser, F.: Role of neuronal signal input in the down-regulation of central noradrenergic receptor function by antidepressant drugs. J. Neurochem. 39: 290-292, 1982.
186. Sulser, F.: Antidepressant treatments; Regulation and adaptation of functional receptor systems. In: Issues in Psychiatry: The Affective Disorders, J.M. Davis and J.W. Maas, eds., American Psychiatric Press, Inc., Washington, D.C., pp. 261-272, 1983.
187. Sulser, F. and Janowsky, A.: Receptors, receptor sensitivity and receptor regulation in the CNS, Advances Biochem. Psychopharmacol. 34: 141-153, 1982.

Fridolin Sulser, M.D.
Curriculum Vitae

188. Mishra, R., Gillespie, D.D., Youdim, M.B.H. and Sulser, F.: Effect of MAO and MAO B inhibition in the norepinephrine (NE) receptor coupled adenylate cyclase system in brain. *Fed. Proc.* 41, 4652, 1982.
189. Sulser, F. and Janowsky, A.: Mechanisms and regulation of recognition and action function of the norepinephrine (NE) receptor coupled adenylate cyclase system in brain: Indications for the therapy of depression. Abstract 13th CINP Congress, Jerusalem, Israel (1982).
190. Janowsky, A.J., Steranka, L.R., Applegate, C.D. and F. Sulser: Lesioning of serotonergic systems by 5,7-dihydroxytryptamine (5,7-DHT) modifies the norepinephrine (NE) receptor coupled adenylate cyclase system in rat brain cortex. Abstract 13th CINP Congress, Jerusalem, Israel (1982).
191. Sulser, F.: Regulation and adaptation of central norepinephrine receptor systems in brain: Modification by antidepressant treatments. *The Psychiatric J. (Univ. of Ottawa)* 1 (3) 196-203, 1982.
192. Sulser, F.: Mode of action of antidepressant drugs. *J. Clin. Psychiat.* 44: 14-20, 1983.
193. Janowsky, A.J., Okada, F., Manier, D.H., Steranka, L. and Sulser, F.: Role of serotonergic input in the regulation of the beta-adrenergic coupled adenylate cyclase system in brain. *Science* 218: 900-901, 1982.
194. Okada, F., Manier, D.H., Janowsky, A.J., Steranka, L.R. and Sulser, F.: Role of aminergic neuronal input in the down-regulation by desipramine (DM1) of the norepinephrine (NE) receptor coupled adenylate cyclase system in rat cortex. *Soc. Neurosci.* 8 (2): 659, 1982 (Abstract).
195. Sulser, F.: Antidepressant treatments and regulation of norepinephrine receptor coupled adenylate cyclase systems in brain. *Advances Biochem. Psychopharmacol* 39: 249-261, 1984.
196. Sulser, F., Janowsky, A., Okada, F., Manier, D.H. and Mobley, P.L.: Regulation of recognition and action function of the norepinephrine receptor coupled adenylate cyclase system in brain: Implications for the therapy of depression. *Neuropharmacology* 22: 425-431, 1983.
197. Sulser, F., Okada, F., Manier, D.H., Gillespie, D.D., Janowsky, A. and Mishra, R.: Noradrenergic Signal transfer as a target of antidepressant therapy. In: *Frontiers in Neuropsychiatric Research*, E. Usdin, M. Goldstein, A. Friedhoff and A. Georgotas, eds., pp. 3-17, MacMillan Press, London, 1983.
198. Sulser, F., Okada, F., Manier, D.H. and Janowsky, A.J.: Regulation of noradrenergic receptor systems in brain that are coupled to adenylate cyclase. *J. Neurotransmission, Supplement* 18, pp. 121-130, 1983.

Fridolin Sulser, M.D.
Curriculum Vitae

199. Manier, D.H., Okada, F., Janowsky, A., Steranka, L.R. and Sulser, F.: Serotonergic denervation changes binding characteristics of beta adrenoceptors in rat cortex. *Europ. J. Pharmacol.* 86: 137-139, 1983.
200. Sulser, F.: Noradrenergic receptor regulation and the action of antidepressants. In: Symposium "Depression and Antidepressants - Recent Events. *Excerpta Medica, Amsterdam*, pp. 24-36, 1983.
201. Sulser, F.: Deamplification of noradrenergic signal transfer by antidepressants: A modified catecholamine - 5HT hypothesis of affective disorders. *Psychopharmacology Bull.* 19: 301-304, 1983.
202. Sulser, F.: The serotonin - noradrenaline link-hypothesis of affective disorders. *Third World Congress of Psychiatry, Vienna, 1983 (Abstract)*.
203. Mobley, P.L., Manier, D.H. and Sulser, F.: Adrenal corticoids regulate the norepinephrine sensitive adenylate cyclase system in brain. *J. Pharmacol. Exp. Ther.* 226: 71-77, 1983.
204. Mishra, R., Gillespie, D.D., Youdim, M. and Sulser, F.: Selective MAO inhibition and noradrenergic receptor function in rat cortex. *Psychopharmacology* 81: 220-224, 1983.
205. Mobley, P.L., Manier, D.H., Smith, H.E. and Sulser, F.: Biochemical and behavioral correlates of dibenzodiazepine, dibenzocycloheptane and dibenzoxepine: Structure-activity relationships. In Preparation for *J. Med. Chem.*
206. Okada, F., Manier, D.H. and Sulser, F.: Normalization by triiodothyronine (T₃) of recognition and action function of the norepinephrine receptor coupled adenylate cyclase system in cortex following propranolol. In preparation for *J. Neurochem.*
207. Sulser, F., La ricerca nel campo dei farmaci antidepressivi: il suo impatto con la neurobiologia e la psicobiologia. (Lorenzini Lecture) *Rass. Clin. Sci.* 58: 199-207, 1982.
208. Gillespie, D.D., Manier, D.H., Steranka, L.R. and Sulser, F.: Tryptophan hydroxylase inhibition by p-chlorophenylalanine (PCPA): Effect on DM1 induced changes of the norepinephrine (NE) receptor coupled adenylate cyclase in rat cortex. *Soc. Neurosci.* 9: 714 1983 (Abstract).
209. Sulser, F.: Regulation and function of noradrenaline receptor systems in brain: Psychopharmacological aspects. *Neuropharmacology* 23: 255-261, 1984.
210. Sulser, F., Gillespie, D.D., Mishra, R. and Manier, D.H.: Desensitization by antidepressants of central norepinephrine receptor systems coupled to adenylate cyclase. *Ann. N.Y. Acad. Sci.* 430: 91-101, 1984.

Fridolin Sulser, M.D.
Curriculum Vitae

211. Sulser, F.: The serotonin-noradrenaline link hypothesis of affective disorders. In: Psychiatry, Vol. 2, P. Pichot, P. Berner, R. Wolf and K. Thau, Eds. pp. 411-416, 1985, Plenum Press, New York, 1985.
212. Manier, D.H., Gillespie, D.D. and Sulser, F.: A pivotal role for serotonin in the down-regulation of beta adrenoceptors by antidepressants: Reversibility of the action of p-chlorophenylalanine (PCPA) by 5-hydroxytryptophan. *Experientia* 40: 1223-1226, 1984.
213. Sulser, F., Gillespie, D. D. and Manier, D. H.: Central beta adrenoceptor regulation and adaptation under physiological and pathophysiological conditions. Abstract 9th International Congress of Pharmacology, London, 1984 (Abstract).
214. Sulser, F., Gillespie, D.D. and Manier, D.H.: Physiological mechanisms and significance of changes in the regulation of beta adrenoceptors by antidepressants. *Clinical Neuropharmacology* 7: 304-306, 1984.
215. Manier, D.H., Gillespie, D.D. and Sulser, F.: Role of 5HT in the regulation of beta adrenoceptors by desipramine (DM1). *Pharmacologist* 26: 455, 1984 (Abstract).
216. Sulser, F., Gillespie, D.D. and Manier, D.H.: Central beta adrenoceptor regulation and adaptation under physiological pathophysiological conditions. *Proc. 9th Internatl. Cong. Pharmacol.* The MacMillan Press, London, 1984, pp. 125-130.
217. Sulser, F.: The "Serotonin-Norepinephrine Link Hypothesis" of affective disorders. APA, Dallas, 1985 (Abstract).
218. Sulser, F.: The serotonin/noradrenaline link and transmembrane signalling: Physiological and pharmacotherapeutic implications. *Advances Pharmacother.* 2: 175-188, 1986.
219. Sulser, F., Conn, P.J., Zawad. J.S. and Sanders-Bush, E.: Molecular aspects of altered transmembrane regulation of the noradrenaline signal by antidepressants. In: Alfred Benzon Symposium #22, Drug Receptors and dynamic processes in cells, J.S. Schou, A. Geisler, S. Norm, eds., pp. 364-379, Munksgaard, Copenhagen, 1986.
220. Sanders-Bush, E., Conn, P.J. and Sulser, F.: The serotonin/noradrenaline linked beta-adrenoceptor system and the mode of action of antidepressants. *Psychopharmacology Bull.* 21:373-378, 1985.
221. Sulser, F.: Die Serotonin-Noradrenalin-Verknüpfung und transmembrane Übertragung: Physiologische und pharmakotherapeutische Implikationen. *Adv. Pharmacother.* 2: 171-184, 1985.

Fridolin Sulser, M.D.
Curriculum Vitae

222. Zawad, J.S. and Sulser, F.: S-Adenosyl-L-methionine modulates phosphatidylethanolamine methyltransferase response to isoproterenol in brain. *European J. Pharmacol.* 124: 157-160, 1986.
223. Sulser, F., Conn, P.J. and Sanders-Bush, E.: Aminergic receptor function: Physiological and pharmacological implications. In: *Proc. IV. World Congress of Biological Psychiatry*, Elsevier (1986).
224. Sulser, F.: Compounds affecting the noradrenergic and serotonergic systems: Neuropharmacology. In: *Proc. IV. World Congress of Biological Psychiatry*, Elsevier (1986).
225. Manier, D.H., Gillespie, D.D., Sanders-Bush, E. and Sulser, F.: The serotonin/noradrenaline link in brain: I. The role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 335, 109-114, 1987.
226. Gillespie, D.D., Manier, D.H., Sanders-Bush, E. and Sulser, F.: The serotonin/norepinephrine link in brain: II. The role of serotonin in the regulation of beta-adrenoceptors in the low agonist affinity conformation. *J. Pharmacol. Exp. Ther.* 244: 154-159, 1988.
227. Janowsky, A. and Sulser, F.: Alpha and Beta adrenoceptors in brain. In: *Psychopharmacology - The Third Generation of Progress*, H.Y. Meltzer, ed., Raven Press, New York, pp. 249-256 (1987).
228. Sulser, F. and Sanders-Bush, E.: The serotonin-norepinephrine link hypothesis of affective disorders: Receptor-receptor interactions in brain. In: *Molecular Basis of Neuronal Responsiveness*, Y.H. Ehrlich, R.H. Lenox, E. Kordecki, W.O. Berry, eds. Plenum Press, NY, pp. 439-502 (1987).
229. Gillespie, D.D., Manier, D.H., Sanders-Bush, E. and Sulser, F.: The role of norepinephrine and serotonin in the regulation of density and function of central beta adrenoceptors and the alteration by DM1. *Pharmacologist* 28: 91, 1986.
230. Sulser, F.: Serotonin-norepinephrine interactions in the brain: Implications for the pharmacology and pathophysiology of affective disorders. *J. Clin. Psychiatry* 48: 12-18, 1987.
231. Sulser, F.: Update on neuroreceptor mechanisms and their implications for the pharmacotherapy of affective disorders. *J. Clin. Psychiatry* 47: 13-18, 1986.
232. Manier, D.H., Gillespie, D.D. and Sulser, F.: 5,7-Dihydroxytryptamine induced lesions of serotonergic neurons and desipramine induced down-regulation of cortical beta adrenoceptors: A re-evaluation. *Biochem. Pharmacol.* 36, 3308-3310, 1987.

Fridolin Sulser, M.D.
Curriculum Vitae

233. Sulser, F.: The State of Neuropsychopharmacology. In: Anniversary Anthology 25 years of Progress. American College of Neuropsychopharmacology, 39-40, 1986.
234. Sanders-Bush, E. and Sulser, F.: Serotonin/norepinephrine receptor interactions. Sensitivity changes after antidepressants and lesions. In: Receptor - receptor interactions: New intramembrane integrative mechanisms, Eds. K. Fuxe, L.F. Agnati, Wenner Gren Symp. No. 48, MacMillan Press Ltd.; pp. 387-397, 1987.
235. Joffe, R.T., Post, R.M., Sulser, F. and Weiss, S.R.B.: Effects of thyroid alterations and carbamazepine on cortical beta-adrenergic receptors in the rat. *Neuropharmacology* 27: 171-174, 1988.
236. Manier, D.H., Gillespie, D.D., Sanders-Bush, E. and Sulser, F.: Dual aminergic control of beta adrenoceptors in rat cerebral cortex. *Fed. Proc.* 46: 430, 1987 (Abstract).
237. Sulser F.: Progress and destiny of neuropsychopharmacology or why I chose a sabbatical in molecular biology. In: Anniversary Anthology, 25 Years of Progress. American College of Neuropsychopharmacology, 167-169, 1986.
238. Sulser, F. and Sanders-Bush, E.: The serotonin/norepinephrine steroid receptor link in brain and the mode of action of antidepressants. In: "New Directions in Affective Disorders", B. Lerer and S. Gershon, eds., Springer-Verlag, New York, NY pp. 85-88, 1989.
239. Sulser, F.: The cascade of the norepinephrine receptor coupled adenylate cyclase-protein kinase system in brain as a target of potential antidepressant treatments. In: International Conference on New Directions in Affective Disorders. Jerusalem, 1987 (Abstract).
240. Manier, D.H., Gillespie, D.D., and Sulser, F.: Dual aminergic Regulation of Central Beta Adrenoceptors: Effect of atypical antidepressants and 5-hydroxytryptophan. *Neuropsychopharmacology* 2: (2) 89-95, 1989.
241. Sulser, F.: New perspectives on the molecular pharmacology of affective disorders. *European Arch. Psychiatry Neurolog. Sci.* 238: 231-237, 1989.
242. Sulser, F.: Molecular-pharmacological Aspects of the Mode of Action of Antidepressants. *Experientia* 44, S39, 1988 (Abstract).
243. Sulser, F. and Sanders-Bush, E.: From Neurochemical to Molecular Pharmacology of Antidepressants. In Tribute to B.B. Brodie, E. Costa, Ed.; Raven Press, New York, 1989, pp. 289-302.
244. Gillespie, D.D., Manier, D.H. and Sulser, F.: Cortical beta adrenoceptors with high (RH) and low agonist affinity (RL): Effect of atypical antidepressants and

Fridolin Sulser, M.D.
Curriculum Vitae

- characterization of the inducible (RL) population. *The Pharmacologist* 30: 847,1988.
245. Gillespie, D.D., Manier, D.H. and Sulser, F.: Characterization of the SHT sensitive dihydroalprenolol binding sites with low affinity for isoproterenol. *Neuropsychopharmacology* 2: 265-271, 1989.
 246. Sulser, F.: Psychopharmacology in transition., Editorial, *Human Psychopharmacology* 4, 1-2 (1989).
 247. Sulser, F.: Mode of action of antidepressants: From traditional biochemical to molecular neuropsychopharmacology. In: *Antidepressants: Thirty Years On*. B. Leonard and P. Spencer, eds. CNS Publishers, London, pp.23-35, 1990.
 248. Sulser, F.: The neurochemistry of refractory depression: A molecular view on therapy-resistant signal transfer. *Adv. Neuropsychiat. Psychopharmacol.* 2: 13-21,1991.
 249. Pryor, J.C. and Sulser, F.: Evolution of monoamine hypotheses of depression. In *Biological Aspects of Affective Disorders*; Eds. R.W. Horton and C. Katona, Academic Press, London, 1991, pp. 77-94.
 250. Manier, D.H. and Sulser, F.: Chronic exposure of rat glioma C6 cells to oxaprotiline reduces the density of beta adrenoceptors. *Soc. Neurosci.* 16, 385, 1990 (Abstract).
 251. Pryor, J.C. and Sulser, F.: Protein kinase C and calcium/ calmodulin kinase II-stimulated protein phosphorylation in the rodent anterior pituitary. *Soc. Neurosci.* 16, 1180, 1990 (Abstract).
 252. Manier, D.H., Bieck, P., DuhI, D.M., Gillespie, D.D. and Sulser, F.: The beta adrenoceptor coupled adenylate cyclase system in rat C6 glioma cells. Deamplification by isoproterenol and oxaprotiline. *Neuropsychopharmacology*, 7, 105-112, 1992.
 253. Eiring, A., Manier, D.H. and Sulser, F.: The "5HT/NE/Link" beyond the beta adrenoceptor. *Soc. Neurosci.* 17, 989, 1991 (Abstract).
 254. Sulser, F.: The Norepinephrine/serotonin/glucocorticoid-Link system as a target of antidepressants. *J. Clin. Pharmacol.* 31, (No. 3), 269, 1991 (Abstract).
 255. DuhI, D.M., Gillespie, D.D., and Sulser, F.: Ethidium bromide fluorescence of 28S ribosomal RNS can be used to normalize samples in northern or dot blots when analyzing small drug-induced changes in specific mRNA. *J. Neurosci. Methods*, 42, 211-218, 1992.

Fridolin Sulser, M.D.
Curriculum Vitae

256. Bieck, P.R., Duhl, D.M., Eiring, A., Gillespie, D.D., Manier, D.H. and Sulser, F.: Dose-dependent down-regulation of I-adrenoceptors by isoproterenol in rat C6 glioma cells. *Europ. J. Pharmacol.*, 225, 171-174, 1992.
257. Eiring, A., Manier, D.H., Bieck, P.R., Howells, R.D. and Sulser, F.: The "Serotonin/Norepinephrine/Glucocorticoid Link" beyond the beta adrenoceptors. *Molec. Brain Res.*, 16, 211-214, 1992.
258. Bieck, P.R., Duhl, D.M., Gillespie, D.D., Manier, D.H., and Sulser, F.: "The beta adrenoceptor-coupled adenylate cyclase system in rat C6 glioma cells as a model system for the study of noradrenergic deamptification." American College of Neuropsychopharmacology, San Juan, Puerto Rico, 1991.
259. Sanders-Bush, E. and Sulser, F.: Chapter #17 Drugs used for the Treatment of Affective Disorders. In: *Textbook Pharmacology in Clinical Practice*, P. Munson, ed., Chapman and Hall, New York, 1995; pp. 309-324.
260. Manier, D.H., Eiring, A. and Sulser, F.: Pharmacological analysis of the "5HT/NE Link" beyond the beta adrenoceptor. *FASEB J.* 1, A395, 1993.
261. Sulser, F.: The aminergic "link hypothesis: of affective disorders: A molecular view of therapy-resistant depression. In *Neurobiology of Affective Disorders; The Third Annual Bristol-Myers Squibb Symposium on Neuroscience Research*. Raven Press, New York, N.Y., 1993, pp. 7-12.
262. Rossby, S.P. and Sulser, F.: Die Wirkmechanismen von Antidepressiva: Ein historischer Ruckblick und neue neurobiologische Aspekte. *ZNS Journal, Forum für Psychiatrie und Neurologie* 1, 10-19, 1993
263. Manier, D.H., Eiring, A. and Sulser, F.: The "serotonin (5HT)/norepinephrine (NE) link" beyond the beta adrenoceptor: Is the 5HT effect mediated via 5HT1B receptors? *J. Serotonin Res.*, 1, 113-118, 1994.
264. Ascher, J, Martin, P., Fibiger, H.C., Golden, R.N., Ferris, R.M., Feighner, J.P., Richelson, E., Sulser, F., Potter, W.Z., Cole, J.O., Apse, J., Weisler, R., Settle, E. and Zisook, S.: Bupropion's mechanism of antidepressant activity: A Review. *J. Clin. Psychiatry*, 56:395-401, 1995.
265. Gillespie, D.D., Duhl, D.M., Manier, D.H. and Sulser, F.: R₁-adrenoceptor mRNA levels can be increased via R-adrenoceptor independent events. *J. Pharm. Pharmacol.*, 47, 62-65, 1995.
266. Rossby, S.P., Huang, M., Burt, A., Gillespie, D.D. and Sulser, F.: The "serotonin/Norepinephrine/glucocorticoid link" as a target for antidepressant drug action. *Neuropsychopharmacology* 10, 173S, 1994.

Fridolin Sulser, M.D.
Curriculum Vitae

267. Shelton, R.C., Manier, D.H. and Sulser, F.: Beta-adrenoceptor stimulated protein kinase A activity in depression. *Neuropsychopharmacology* 10, 11 8S, 1994 (Abstract).
268. Shelton, R.C., Manier, D.H. and Sulser, F.: Cyclic cAMP-dependent protein kinase activity in major depression. *Amer. J. Psychiatry*, 153:1037-1042, 1996
269. Rossby, S.P., Nalepa, I., Huang, M., Burt, A., Perrin, C., Schmidt, D.E. and Sulser, F.: Norepinephrine-independent regulation of GR11 mRNA in vivo by a tricyclic antidepressant. *Brain Res.* 687:79-82, 1995
270. Manier, D.H., Eiring, A., Shelton, R.C., and Sulser, F.: Beta-adrenoceptor linked PKA activity in human fibroblasts from normal subjects and from patients with major depression. *FASEB J.* 9, A108, 1995.
271. Rossby, S.P., Nalepa, I., Burt, A., Perrin, C., Schmidt, D.E. and Sulser, F.: Norepinephrine-independent regulation of steady-state glucocorticoid receptor (Type II) mRNA levels in vivo by a tricyclic antidepressant drug. *FASEB J.* 9, A408, 1995.
272. Manier, D.H., Eiring, A., Shelton, R.C. and Sulser, F.: Beta adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and patients with major depression. *Neuropsychopharmacology* 15:555-561, 1996.
273. Sulser, F.: The noradrenergic component of mechanisms of action of antidepressants and current hypotheses of affective disorders. *J. Clin. Psychiatry*, 1998 (in press).
274. Eiring, A., Manier, D.H., Shelton, R.C. and Sulser, F.: Immediate early gene induction in human fibroblasts from normal subjects and from patients with major depression. *Soc. Neurosci.* 21, 594, 1995
275. Rossby, S.P., Perrin, C., Burt, A., Nalepa, I., Spector, S. and Sulser, F.: Fluoxetine increases steady-state levels of preproenkephalin mRNA in rat striatum and amygdala. *Soc. Neurosci.* 21, 1694, 1995
276. Nemeroff, C.B., Charney, D.S., Evans, D.L., Kahn, N.H., Nelson, CT, Owens, M.J., Preskorn, L.H., Schatzberg, A.F., Siever, L.J. and Sulser, F.: The role of specific neurotransmitter systems in the pathophysiology and treatment of depression. Implications for serotonin-norepinephrine reuptake inhibitors. *Churchill Comm. NCC CME Workshop*; pp. 1-16,1996.
277. Rossby, S.P., Perrin, C.; Burt, A., Nalepa, I., Schmidt, D.E. and Sulser, F.: Fluoxetine increases steady-state levels of preproenkephalin mRNA in rat amygdala by a serotonin dependent mechanism. *J. Serotonin Res.* 3, 69-74, 1996.

Fridolin Sulser, M.D.
Curriculum Vitae

278. Chkrabarti, A., Rossby, S.P., Manier, D.H., Perrin, C., Onaivi, E.S. and Sulser, F.: Molecular correlates of a chronic mild stress model of depression. *Soc. Neurosci.* 22:2060 (809.15), 1996.
279. Sulser, F.: Psychopharmacology in Transition. *ACNP Anthology*, 1997, pp.92-93.
280. Eiring, A. and Sulser, F.: An increased synaptic availability of norepinephrine is not essential for antidepressant induced increases in hippocampal GR mRNA. *J. Neural Transmission*, 104:1255-1258, 1997.
281. Rossby, S.P. and Sulser, F.: Antidepressants: Events beyond the synapse. In *Antidepressants: New Pharmacological Strategies*, Phil Skolnick, ed., The Humana Press Inc., Totowa, NY 1997, pp. 195-212.
282. Chakrabarti, A., Onaivi, E., Sulser, F., and Akinshola, B.E.: Interaction of cannabinoids with NMDA and non-NMDA glutamate receptors. *Soc. Neurosci.* 23:376.11, 1997.
283. Nalepa, I., Manier, D.H., Gillespie, D.G., Rossby, S.P., Schmidt, D.E., and Sulser, F.: Lack of Beta Adrenoceptor Desensitization in Brain Following the Dual Noradrenaline and Serotonin reuptake inhibitor venlafaxine. *European Neuropsychopharmacology*, 8:227-232, 1998.
284. Spector, S. and Sulser, F.: Neuropsychopharmacology. In *Current Diagnosis and Treatment in Psychiatry*, Ebert, M.H., Loosen, P.T., Nurcombe, B. eds., Appleton and Lange, East Norwalk, 2000, pp. 29-39.
285. Rossby, S.P. and Sulser, F.: Antidepressants and post-receptor events: The "Serotonin/norepinephrine Link" revisited. In *Antidepressant Therapy at the Dawn of the 3 Millenium*; M. Briley and S.A. Montgomery, eds., Martin Dunitz Ltd., London, 1998, pp. 69-86.
286. Rossby, S.P., Manier, D.H., Liang, S., Nalepa, I., and Sulser, F.: Pharmacological Actions of the antidepressant venlafaxine beyond aminergic receptors. *Intl. J. Neuropsychopharmacol.* 2, 1-8, 1999.
287. Sulser, F.: The 1960s: My early years with tricyclics. In *The rise of Psychopharmacology*, T.A. Ban, D. Healy, E. Shorter, eds.; Animula Publishing House, Budapest, 1998, pp. 81-84.
288. Shelton, R.C., Manier, D.H., Ellis, T., Sulser, F.: Blunted protein kinase A (PKA) activity in human fibroblasts from patients with major depression. *Soc. Neurosci.* 24, 224 (90.1), 1998.
289. Sulser, F.: The evolution of the mode of action of antidepressants: A forty

Fridolin Sulser, M.D.
Curriculum Vitae

- year journey from presynaptic to nuclear events. *The Internatl. J. Neuropsychopharmacol.* 1, S88, 1998.
290. Shelton, R.C. Manier, D.H., Ellis, T. Peterson, Ch.S. and Sulser, F.: Cyclic AMP dependent protein kinase in subtypes of major depression and normal volunteers. *The Internatl. J. Neuropsychopharmacol.*, 3:187-192, 1999.
291. Manier, D.H., Shelton, R.C., Ellis, T. Peterson, Ch.S., Eiring, A. and Sulser, F.: Human fibroblasts as a relevant model of signal transduction in affective disorders. *J. of Affective Disorders* 61:51-58, 2000.
292. Sulser, F.: From the presynaptic neurone to the receptor to the nucleus. In *The Psychopharmacologists, III*; D. Healy, Ed., 2000 Arnold, London and Oxford Press, New York, 2000 pp. 239-258.
293. Sulser, F.: How do antidepressants influence signal transduction cascades beyond aminergic receptors? *Acta Neurobiol. Exp.* 59:255 (31.2), 1999.
294. Manier, D.H., Shelton, R.C. and Sulser, F.: Cross-talk between PKA and PKC in human fibroblasts: The convergence of neurotransmitter signals beyond receptors and its implications for the mode of action of antidepressants. *J. Affective Disorders* 65:275-279, 2001.
295. Rossby, S.P., Liang, S., Manier, D.H., Shelton, R.C., and Sulser, F.: Altered programs of gene expression in human fibroblasts from patients with major depression. *Biol. Psychiatry*, 47, 198, 2000.
296. Rossby S.P., Liang, S., Manier, D.H., Chakrabarti, A., Shelton, R.C., and Sulser, F.: Molecular psychopharmacology as a prelude to a molecular psychopathology of affective disorders; The significance of differential display methodology to study programs of gene expression. In *Molecular Genetics of Mental Disorders*; M. Briley and F. Sulser eds., Martin Dunitz, Ltd., London, 2000 pp. 31-46.
297. Shelton, R.C., Manier, D. H., Rossby, S.P., Liang, S. and Sulser, F.: Transductional mechanisms and gene expression in melancholia. *Biol. Psychiatry*, 47, 430, 2000.
298. Nalepa, I., Kowalska M., Vetulani J., Zelek-Molik, A. and Sulser, F.: Effects of repeated treatment with venlafaxine on alpha, adrenergic receptor subtypes. *Internatl. J. Neuropsychopharmacol.* 3, S187, 2000.
299. Chakrabarti, A; Manier, D.H., Shelton, R.C., Sulser F., Papp, M. and Nalepa, I.: Molecular correlates of a chronic mild stress model of depression. *Soc. Neurosci.* 2000, 26, 866.20.
300. Liang, S., Rossby, S.P., Shelton C. R., Chakrabarti, A., Manier, D.H. and

- Sulser, F.: Detection of an mRNA polymorphism by differential display. *Molec. Biotechnology*, 19: 121-124,2001.
301. Shelton, R.C., Liang, S., Rossby, S.P., Chakrabarti, A, Manier, D.H. and Sulser, F.: Differential expression of PTX3 in fibroblasts of patients with major depression. *Neuropsychopharmacol.*, 29: 126-132,2004.
302. Briley, M. and Sulser, F., eds. *Molecular Genetics of Mental Disorders*. Martin Dunitz, Ltd., London 2001.
303. Shelton, R.C., Liang, S., Chakrabarti, A., Manier, D.H., Rossby, S.P. and Sulser, F. : Programs of gene expression in human fibroblasts from patients with Major depression. *ACNP*, 2000: 160.
304. Nalepa, I. and Sulser, F. : Antidepressant Drugs: Towards the discovery of the next generation based on current hypotheses of their mode of action. In *Handbook of Experimental Pharmacology*, W. Boyer and J. Feighner, eds., Springer - Verlag, Berlin, Heidelberg, 2004, pp. 519-563.
305. Manier, D.H., Shelton, R.C. and Sulser, F.: Noradrenergic Antidepressants: Does chronic treatment increase or decrease nuclear CREB-P? *J. Neural Transm.* 109: 91 —99, 2002.
306. Sulser, F.: Cellular signal transduction cascades as molecular amplification - adaptation systems: A pharmacologist's view on CNS plasticity and psychopathology. *Acta neurobiol. Experiment.* 61:186, 2001.
307. Sulser, F.: The role of CREB and other transcription factors in the etiology and Pharmacotherapy of depression. *Ann. Med.* 34: 348-356, 2002.
308. Sulser, F.: My becoming a psychopharmacologist: New Drugs and new Concepts. An Autobiographical Account. In "The History of Psychopharmacology and the CINP - as told in Autobiography, T.A. Ban, D. Healy and E. Shorter, eds., Animula Publishing House, Budapest, 2004; pp. 299 - 307.
309. Sulser, F.: Norepinephrine and the Neurotransmitter Era in Neuropsychopharmacology.

In: *The Neurotransmitter Era in Neuropsychopharmacology*. Thomas A. Ban and Ronaldo Ucha Udabe, Eds., 2006. Editorial Polemos, Argentina; pp. 53 -64.

310. Sulser, F. : Tribute to Oakley Ray. Reflections. In: *ACNP Bulletin*, volume 12, 2006.

311. Sulser, F. : From the early days with Tricyclics to studies on the convergence of neuronal, endocrine and immune signal cascades. *Internatl.J. Neuropsychopharmacology* 11: 12, 2008.

312. Sulser, F.: Reflections. *ACNP Monograph*, 50 years, 2010.